Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Paolo Calabrò et al.|Cardiovascular Diabetology|2022Cited by 206
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Ciro Mauro et al.|Pharmacological Research|2022Cited by 146
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patientsRaffaele Marfella, Giuseppe Paolisso, Pasquale Paolisso et al.|Diabetes & Metabolism|2020Cited by 138
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCAPasquale Paolisso, Carmine Pizzi, Alberto Foà et al.|Cardiovascular Diabetology|2021Cited by 126
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCAPasquale Paolisso, Carmine Pizzi, Alberto Foà et al.|Cardiovascular Diabetology|2021Cited by 124